Browsing by Author Garbe, Claus

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 9 of 9
Issue DateTitleAuthor(s)Citation
2014Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanomaLong, Georgina; Chiarion-Sileni, Vanna; De Braud, Filippo; et al, Various; Garbe, Claus; Gogas, Helen; Grob, Jean Jacques; Hauschild, Axel; Jouary, Thomas; Larkin, James; Levchenko, Evgeny; Stroyakovskiy, Daniil; Central Clinical School: The Sydney Cancer CentreCombined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma, The New England Journal of Medicine, vol.371, 20, 2014,pp 1877-1888
2015Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trialLong, Georgina; Chiarion-Sileni, Vanna; De Braud, Filippo; et al, Various; Garbe, Claus; Gogas, Helen; Grob, Jean-Jacques; Hauschild, Axel; Jouary, Thomas; Larkin, James; Levchenko, Evgeny; Stroyakovskiy, Daniil; Central Clinical School: The Sydney Cancer CentreDabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial, The Lancet, vol.386, 9992, 2015,pp 444-451
2014Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013Kefford, Richard (Rick); Anderson, Ana Carrizosa; Ascierto, Paolo; Bifulco, Carlo; Cochran, Alistair J.; Eggermont, Alexander; et al, Various; Faries, Mark B.; Ferrone, Soldano; Garbe, Claus; Gershenwald, Jeffrey E.; Grimaldi, Antonio; Western Clinical School: Westmead Millennium InstituteFuture perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013, Journal of Translational Medicine, vol.12, N/A, 2014,pp 1-29
2010Genetic and morphologic features for melanoma classificationMcCarthy, Stanley; Scolyer, Richard; Barnhill, Raymond; Bauer, Jurgen; Boris, Bastian; Broekaert, Sigrid; Busam, Klaus; Cochran, Alistair; Cook, Martin; Elder, David E; Garbe, Claus; Mihm, Martin; Okamoto, Ichiro; Roy, Ritu; Schadendorf, Dirk; Spatz, Alan; van den Oord, Joost; Central Clinical School: Inst. of Anatomical Pathology RPAH; Central Clinical School: PathologyGenetic and morphologic features for melanoma classification, Pigment Cell & Melanoma Research, vol.23, 6,pp 763-770
2015Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanomaLong, Georgina; Amonkar, Mayur M; Bondarenko, Igor; de Braud, Filippo; et al, Various; Garbe, Claus; Gogas, Helen; Grob, Jean-Jacques; Lebbe, Celeste; Levchenko, Evgeny; Schadendorf, Dirk; Stroyakovskiy, Daniil; Central Clinical School: The Sydney Cancer CentreHealth-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma, European Journal of Cancer, vol.51, 7, 2015,pp 833-840
2012Improved Survival with MEK Inhibition in BRAF-Mutated MelanomaHersey, Peter; Demidov, Lev; Drummer, Reinhard; et al, Various; Flaherty, Keith; Garbe, Claus; Hassel, Jessica; Milhem, Mohammed; Mohr, P; Nathan, Paul; Robert, Caroline; Rutkowski, Piotr; Northern Clinical School: SurgeryImproved Survival with MEK Inhibition in BRAF-Mutated Melanoma, New England Journal of Medicine, vol.367, 2, 2012,pp 107-114
2013Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanomaKefford, Richard (Rick); et al, Various; Garbe, Claus; Gogas, Helen; Haanen, John; Linette, Gerald; Lorigan, Paul; Marmol, Maribel; Marshall, Margaret A.; Punt, Cornelis J.A.; Ribas, Antoni; Schachter, Jacob; Western Clinical School: Westmead Millennium InstitutePhase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma, Journal of Clinical Oncology, vol.31, 5, 2013,pp 616-622
2015The Prognostic and Predictive Value of Melanoma-related MicroRNAs Using Tissue and Serum: A MicroRNA Expression AnalysisHaydu, Lauren; Long, Georgina; Mann, Graham; Scolyer, Richard; Thompson, John; Barbour, Andrew; Garbe, Claus; Hayward, Nicholas K; Herington, Adrian; Klein, Kerenaftali; Palmer, Jane M; Pflugfelder, Annette; Pollock, Pamela M; Soyer, H Peter; Stark, Mitchell S; Tang, Yue Hang; Weide, Benjamin; Whiteman, David C.; Central Clinical School: Surgery; Central Clinical School: The Sydney Cancer Centre; Western Clinical School: Westmead Institute for Medical Res; Central Clinical School: Pathology; Central Clinical School: SurgeryThe Prognostic and Predictive Value of Melanoma-related MicroRNAs Using Tissue and Serum: A MicroRNA Expression Analysis, EBioMedicine, vol.2, 7, 2015,pp 671-680
2017Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trialsLong, Georgina; Chiarion-Sileni, Vanna; Dutriaux, Caroline; et al, Various; Garbe, Claus; Hauschild, Axel; Karaszewska, Boguslawa; Levchenko, Evgeny; Schachter, Jacob; Schadendorf, D; Stroiakovski, Daniel; Northern Clinical School: MedicineThree-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials, European Journal of Cancer, vol.82, N/A, 2017,pp 45-55